Jasper is excited to host a key opinion leader webinar on the potential of briquilimab in chronic urticaria. The event will begin at 8:00am EST tomorrow, 10/11. Link to register: https://t.co/JEwNz5f4sQ
Jasper Therapeutics is pleased to announce that the FDA has accepted our IND application for briquilimab in #ChronicSpontaneousUrticaria. We look forward to initiating our phase 1b/2a study in CSU later this year. Read the full announcement: https://t.co/tutu4nklSn
Jasper is excited to announce the addition of Patricia Carlos (SVP, Regulatory Affairs and Quality) and Annette Marcantonio (VP, Clinical Operations) to the team! https://t.co/nE3EGBDudj
Today we announced the first patient dosed in a Phase 1 trial, which is evaluating briquilimab’s therapeutic potential in targeting c-Kit for people with low-risk myelodysplastic syndrome. Read more: https://t.co/79kEEc3ldp #MDS
Today, we announced the appointment of Dr. Scott Brun to our Board of Directors. His 20+ years of drug development experience makes him an excellent asset as we advance briquilimab in chronic mast cell and stem cell-driven disease. Full announcement: https://t.co/AQcRgJWbnN
Thrilled to announce Dr. Edwin J. Tucker has joined as our new CMO. An accomplished #biotech and large pharma exec, his expertise will be invaluable as our clinical programs expand. Acting CMO, Dr. Daniel Adelman, will join our Scientific Advisory Board. https://t.co/0iw0YPdqOt
At Jasper, we believe in the power of diversity and inclusivity. This #PrideMonth, let’s celebrate the LGBTQ+ community by creating a world where everyone can live their lives with love, acceptance, and equal opportunities. 🏳️🌈
This World Blood Cancer Day, we share in bringing awareness to current limited treatment options. We’re joining the fight by exploring how targeting c-Kit may offer a new approach for people with low-to-intermediate risk myelodysplastic syndromes (#MDS). #WBCD
We recently celebrated the Jasper lab team and the critical role they play in advancing our therapeutic pipeline targeting c-Kit for chronic mast and stem cell diseases. Thank you for your invaluable contributions – you make our work possible! #LabWeek2023#TheFutureisLab
Our Senior VP of Research and Translational Medicine, Dr. Wendy Pang, is featured in an @AuthorityMgzine series highlighting inspirational women in STEM and tech. Read the full article to learn about her advice for building a successful career in #biotech: https://t.co/kSZugbaC5u
Today we announced Dr. Stephen J. Galli as the newest addition to our Scientific Advisory Board. He is a recognized researcher on the biology and pathology of mast cells, and he joins us as we advance our work in targeting c-Kit for #mastcell diseases. https://t.co/uvjTGGT90V
We are thrilled to announce the appointment of Matt Ford as our new Vice President, Human Resources. We’re excited to welcome him to help further build our Jasper team! https://t.co/w1zcucCDH6
We’re happy to welcome David Hinds as our Senior Vice President of Development Operations. With 25+ years of experience in operations and clinical program development, his leadership will be instrumental in helping advance our current and future studies. https://t.co/8bR13s4DoY
We’re thrilled to welcome Dr. Daniel Adelman as our new Acting Chief Medical Officer! His extensive experience in clinical development of novel therapies for #immunologic diseases will be vital to our team. Read more: https://t.co/9YX1jAXZh4
Our CEO Ron Martell will present at two upcoming investor conferences this month. Join us at @WilliamBlair’s Innovator Series: What’s Next in Dermatology? and the @Oppenheimer 33rd Annual Healthcare Conference. Learn more here: https://t.co/QAijkT1AdF #OPCOHC2023
Today in recognition of International Women’s Day, we asked Jasper SVP Wendy Pang to share what this year’s theme #EmbraceEquity means to her. #IWD2023
ICYMI: @TargetedOnc interviewed Lori Muffly, MD, about briquilimab data presented at #Tandem23 showing promise for targeting c-Kit in MDS/AML undergoing alloHCT. Read the full interview: https://t.co/ENdZVMlH1k